Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862–873

Article  Google Scholar 

Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol 2021;13:17524123

Article  Google Scholar 

Zhang X, Wang J, Shi J, Jia X, Dang S, Wang W. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. JAMA Netw Open 2021;4(4): e214846

Article  Google Scholar 

Patwala K, Prince DS, Celermajer Y, Alam W, Paul E, Strasser SI, et al. Lenvatinib for the treatment of hepatocellular carcinoma-a real-world multicenter Australian cohort study. Hepatol Int 2022;16(5):1170–1178

Article  Google Scholar 

Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. BBA-Rev Cancer 2020;1874(1): 188391

Google Scholar 

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7(1):6

Article  Google Scholar 

Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2020;38(26):2960–2970

Article  Google Scholar 

Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J HEPATOL 2020;72(2):288–306

Article  Google Scholar 

Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, et al. Weekends-Off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers 2020;12(4):1010

Article  Google Scholar 

Morimoto M, Numata K, Kondo M, Kobayashi S, Ohkawa S, Hidaka H, et al. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: a propensity score analysis. Hepatol Res 2015;45(3):279–287

Article  Google Scholar 

Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592(7854):450–456

Article  Google Scholar 

Cho H, Kang H, Lee HH, Kim CW. Programmed cell death 1 (PD-1) and cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis. Int J Mol Sci 2017;18(7):1517

Article  Google Scholar 

Torrens L, Montironi C, Puigvehi M, Mesropian A, Leslie J, Haber PK, et al. Immunomodulatory effects of Lenvatinib plus anti-programmed cell death protein 1 in Mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology 2021;74(5):2652–2669

Article  Google Scholar 

Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology 2021;74(5):2544–2560

Article  Google Scholar 

Wei CY, Zhu MX, Zhang PF, Huang XY, Wan JK, Yao XZ, et al. PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol 2022;77(1):163–176

Article  Google Scholar